Journal
CHEMICAL SCIENCE
Volume 5, Issue 6, Pages 2398-2406Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c4sc00451e
Keywords
-
Categories
Funding
- NIH [P01HL107151, RO1CA138891, T32AI007606, GM087620]
- Human Frontiers Fellowship
- Schering-Plough Research Institute Postdoctoral Fellowship
- Netherlands Organization For Scientific Research
- NATIONAL CANCER INSTITUTE [R01CA138891] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL107151] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007606, R01AI099141] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087620] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The siglec family of sialic acid-binding proteins are endocytic immune cell receptors that are recognized as potential targets for cell directed therapies. CD33 and CD22 are prototypical members and are validated candidates for targeting acute myeloid leukaemia and non-Hodgkin's lymphomas due to their restricted expression on myeloid cells and B-cells, respectively. While nanoparticles decorated with high affinity siglec ligands represent an attractive platform for delivery of therapeutic agents to these cells, a lack of ligands with suitable affinity and/or selectivity has hampered progress. Herein we describe selective ligands for both of these siglecs, which when displayed on liposomal nanoparticles, can efficiently target the cells expressing them in peripheral human blood. Key to their identification was the development of a facile method for chemo-enzymatic synthesis of disubstituted sialic acid analogues, combined with iterative rounds of synthesis and rapid functional analysis using glycan microarrays.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available